C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 312—Investigational New Drug ApplicationSubpart B—Investigational New Drug Application (Ind)

21 C.F.R. § 312.32 (2026)

IND safety reporting

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1992–2022 21citing cases
At a glance

Courts have cited this section in 21 opinions since 1992, 3 of them in the last five years. The most litigated part is subsection (a) (1 case).

Link to an amendment published at 91 FR 60003, Sept. 22, 2026.

(a) Definitions. The following definitions of terms apply to this section:

Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Life-threatening adverse event or life-threatening suspected adverse reaction. An adverse event or suspected adverse reaction is considered “life-threatening” if, in the view of either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event or serious suspected adverse reaction. An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the investigator or sponsor, it results in any of the following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

Suspected adverse reaction means any adverse event for which there is a reasonable possibility that the drug caused the adverse event. For the purposes of IND safety reporting, “reasonable possibility” means there is evidence to suggest a causal relationship between the drug and the adverse event. Suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.

Unexpected adverse event or unexpected suspected adverse reaction. An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure listed only cerebral vascular accidents. “Unexpected,” as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation.

(b) Review of safety information. The sponsor must promptly review all information relevant to the safety of the drug obtained or otherwise received by the sponsor from foreign or domestic sources, including information derived from any clinical or epidemiological investigations, animal or in vitro studies, reports in the scientific literature, and unpublished scientific papers, as well as reports from foreign regulatory authorities and reports of foreign commercial marketing experience for drugs that are not marketed in the United States.

(c)(1) IND safety reports. The sponsor must notify FDA and all participating investigators (i.e., all investigators to whom the sponsor is providing drug under its INDs or under any investigator's IND) in an IND safety report of potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar days after the sponsor determines that the information qualifies for reporting under paragraph (c)(1)(i), (c)(1)(ii), (c)(1)(iii), or (c)(1)(iv) of this section. In each IND safety report, the sponsor must identify all IND safety reports previously submitted to FDA concerning a similar suspected adverse reaction, and must analyze the significance of the suspected adverse reaction in light of previous, similar reports or any other relevant information.

(i) Serious and unexpected suspected adverse reaction. The sponsor must report any suspected adverse reaction that is both serious and unexpected. The sponsor must report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event, such as:

(A) A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome);

(B) One or more occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture);

(C) An aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group.

(ii) Findings from other studies. The sponsor must report any findings from epidemiological studies, pooled analysis of multiple studies, or clinical studies (other than those reported under paragraph (c)(1)(i) of this section), whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug. Ordinarily, such a finding would result in a safety-related change in the protocol, informed consent, investigator brochure (excluding routine updates of these documents), or other aspects of the overall conduct of the clinical investigation.

(iii) Findings from animal or in vitro testing. The sponsor must report any findings from animal or in vitro testing, whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug, such as reports of mutagenicity, teratogenicity, or carcinogenicity, or reports of significant organ toxicity at or near the expected human exposure. Ordinarily, any such findings would result in a safety-related change in the protocol, informed consent, investigator brochure (excluding routine updates of these documents), or other aspects of the overall conduct of the clinical investigation.

(iv) Increased rate of occurrence of serious suspected adverse reactions. The sponsor must report any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.

(v) Submission of IND safety reports. The sponsor must submit each IND safety report in a narrative format or on FDA Form 3500A or in an electronic format that FDA can process, review, and archive. FDA will periodically issue guidance on how to provide the electronic submission (e.g., method of transmission, media, file formats, preparation and organization of files). The sponsor may submit foreign suspected adverse reactions on a Council for International Organizations of Medical Sciences (CIOMS) I Form instead of a FDA Form 3500A. Reports of overall findings or pooled analyses from published and unpublished in vitro, animal, epidemiological, or clinical studies must be submitted in a narrative format. Each notification to FDA must bear prominent identification of its contents, i.e., “IND Safety Report,” and must be transmitted to the review division in the Center for Drug Evaluation and Research or in the Center for Biologics Evaluation and Research that has responsibility for review of the IND. Upon request from FDA, the sponsor must submit to FDA any additional data or information that the agency deems necessary, as soon as possible, but in no case later than 15 calendar days after receiving the request.

(2) Unexpected fatal or life-threatening suspected adverse reaction reports. The sponsor must also notify FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than 7 calendar days after the sponsor's initial receipt of the information.

(3) Reporting format or frequency. FDA may require a sponsor to submit IND safety reports in a format or at a frequency different than that required under this paragraph. The sponsor may also propose and adopt a different reporting format or frequency if the change is agreed to in advance by the director of the FDA review division that has responsibility for review of the IND.

(4) Investigations of marketed drugs. A sponsor of a clinical study of a drug marketed or approved in the United States that is conducted under an IND is required to submit IND safety reports for suspected adverse reactions that are observed in the clinical study, at domestic or foreign study sites. The sponsor must also submit safety information from the clinical study as prescribed by the postmarketing safety reporting requirements (e.g., §§ 310.305, 314.80, and 600.80 of this chapter).

(5) Reporting study endpoints. Study endpoints (e.g., mortality or major morbidity) must be reported to FDA by the sponsor as described in the protocol and ordinarily would not be reported under paragraph (c) of this section. However, if a serious and unexpected adverse event occurs for which there is evidence suggesting a causal relationship between the drug and the event (e.g., death from anaphylaxis), the event must be reported under § 312.32(c)(1)(i) as a serious and unexpected suspected adverse reaction even if it is a component of the study endpoint (e.g., all-cause mortality).

(d) Followup. (1) The sponsor must promptly investigate all safety information it receives.

(2) Relevant followup information to an IND safety report must be submitted as soon as the information is available and must be identified as such, i.e., “Followup IND Safety Report.”

(3) If the results of a sponsor's investigation show that an adverse event not initially determined to be reportable under paragraph (c) of this section is so reportable, the sponsor must report such suspected adverse reaction in an IND safety report as soon as possible, but in no case later than 15 calendar days after the determination is made.

(e) Disclaimer. A safety report or other information submitted by a sponsor under this part (and any release by FDA of that report or information) does not necessarily reflect a conclusion by the sponsor or FDA that the report or information constitutes an admission that the drug caused or contributed to an adverse event. A sponsor need not admit, and may deny, that the report or information submitted by the sponsor constitutes an admission that the drug caused or contributed to an adverse event.

[75 FR 59961, Sept. 29, 2010]
The 20 cases that cite 21 C.F.R. § 312.32 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBrennan v. Zafgen, Inc., 853 F.3d 606 (1st Cir. 2017).
cites § 312.32 2×cited by 32 cases
Where it cites § 312.32
“The investors’ complaint, however, concentrates on Zafgen’s ZAF-201 trial, a Phase II trial that consisted of 160 patients and lasted from August 2012 to May 2013.”
The case’s holding
A complaint lacking direct evidence of scienter must rely on indirect evidence that is sufficient to raise a strong inference of fraudulent intent.
Later courts cite it for
“where a complaint is devoid of any direct-evidence allegations, the indirect-evidence allegations in the complaint will need to do more work to carry the burden of raising a 'strong inference of scienter' on their own.” · 3 citing courts
2
GREENByrd v. Janssen Pharm., Inc., 333 F. Supp. 3d 111 (N.D.N.Y. 2018).
cites § 312.32 6×subsections: (a)cited by 4 cases
Where it cites § 312.32
“The Court will also set aside the fact that any inpatient hospitalization (at a psychiatric facility) that Plaintiff may still need due to his gynecomastia has (by definition) not been prevented by his 2014 surgery, 8 making it impossible to conclude that gynecomastia has…”
3
GREENCarl Schwartz v. Arena Pharm., Inc., 840 F.3d 698 (9th Cir. 2016).
cites § 312.32 1×cited by 99 cases
Where it cites § 312.32
“See 21 C.F.R. § 312.32 (c)(l)(v)(3) *702 (giving FDA regulatory flexibility in demanding interim safety reports).”
The case’s holding
Defendants who tout positive information to the market must disclose adverse information that cuts against those claims to avoid misleading investors.
Later courts cite it for
“once defendants choose to tout' positive information to the market, 'they are bound to do so in a manner that wouldn't mislead investors,' including disclosing adverse information that cuts against the positive information.” · 9 citing courts
4
GREENIn re Abilify (Aripiprazole) Prods. Liab. Litig., 299 F. Supp. 3d 1291 (N.D. Fla. 2018).
cites § 312.32 1×cited by 23 cases
Where it cites § 312.32
“); 21 C.F.R. § 312.32 (Investigational new drug application safety reporting.”
The case’s holding
A weight-of-the-evidence approach to establishing causation is reliable if the expert carefully considers all available data and explains how the relative weight of the evidence supports the conclusion.
Later courts cite it for
“the difficulty with case reports is distinguishing between association and causation” · 6 citing courts
5
GREENIn re Neurontin Mktg., Sales Practices, & Prods. Liab. Litig., 612 F. Supp. 2d 116 (D. Mass. 2009).
cites § 312.32 1×cited by 36 cases
Where it cites § 312.32
“at 102) (citing 21 C.F.R. § 312.32 (a)). Seventy-eight “serious” adverse events were identified (from the 2048 patients exposed), including seven reports of depression (each involving suicidal ideation), six of drug overdoses, and two suicide attempts.”
The case’s holding
Expert testimony on general causation is admissible under Rule 702 even without epidemiological studies if supported by other evidence such as biological plausibility.
Later courts cite it for
“do not provide as much information as controlled epidemiological studies do.” · 3 citing courts
6
GREENHirtenstein v. Cempra, Inc., 348 F. Supp. 3d 530 (M.D.N.C. 2018).
cites § 312.32 3×cited by 2 cases
Where it cites § 312.32
“46 ¶ 57 (citing 21 C.F.R. § 312.32 (c)(1)(i)(A) ) ); 21 C.”
Later courts cite it for
“statements of opinion are generally actionable only if the plaintiff establishes that the statement was objectively false and the issuer lacked a rational belief in the veracity of the statement at the time it was made.” · 1 citing court
7
GREENFerretti v. Pfizer Inc., 855 F. Supp. 2d 1017 (N.D. Cal. 2012).
cites § 312.32 1×cited by 19 cases
Where it cites § 312.32
“” Under 21 C.F.R. § 312.32 (c)(1), a sponsor “must notify FDA and all participating investigators .”
Later courts cite it for
“wrongful termination in violation of public policy is a california common law 19 cause of action providing that 'when an employer's discharge of an employee violates 20 fundamental principles of public policy, the discharged employee may maintain a tort 21 action and recover damages traditionally available in such actions.” · 3 citing courts
8
GREENSeufert v. Merck Sharp & Dohme Corp., 187 F. Supp. 3d 1163 (S.D. Cal. 2016).
cites § 312.32 1×cited by 5 cases
Where it cites § 312.32
“Accordingly, the Court properly considers the FDA’s review of all incretin mimetics in evaluating whether the FDA would have rejected a labeling change to Onglyza or Kombiglyze. . Federal regulations define an adverse event as "any untoward medical event associated with the use…”
9
GREENBrennan v. Zafgen, Inc., 199 F. Supp. 3d 444 (D. Mass. 2016).
cites § 312.32 1×cited by 3 cases
Where it cites § 312.32
“The results appearing below this statement indicate that, among other things, “[l]evels of the cardiovascular disease risk marker C-reactive protein were reduced by an average of 2,5, 2,3 and 1,9 pg/ml, or 23%, 22% and 37%, respectively, for patients treated with Beloranib at 0.”
10
GREENIn re Eli Lilly & Co., 142 F.R.D. 454 (S.D. Ind. 1992).
cites § 312.32 1×cited by 10 cases
Where it cites § 312.32
“Physicians and hospitals, on the other hand, are merely encouraged to make voluntary adverse reaction reports and drug experience reports, either to the FDA or to the drug manufacturers themselves, usually on FDA Form 1639.”
11
GREENUnited States v. Najarian, 915 F. Supp. 1460 (D. Minn. 1996).
cites § 312.32 1×cited by 7 cases
Where it cites § 312.32
“§§ 331 (e), 355(i) and 333(a)(2), and 21 C.F.R. § 312.32 (c); with one Count of conspiring to commit offenses against the United States, in violation of Title 18 U.”
12
GREENMohr v. Targeted Genetics, Inc., 690 F. Supp. 2d 711 (C.D. Ill. 2010).
cites § 312.32 1×cited by 2 cases
Where it cites § 312.32
“Adverse event reporting ( 21 C.F.R. §§ 312.32 (c)(l)(i)(A), 314.80(a) & (c)(1), 601.”
13
GREENIn re Zofran (Ondansetron) Prods. Liab. Litig., 368 F. Supp. 3d 94 (D.D.C. 2019).
cites § 312.32 1×cited by 1 case
Where it cites § 312.32
“" 21 C.F.R. § 312.32 (a). A similar approach was adopted by the court in McGee v.”
14
NO FLAGRisperdal & Invega Cases, No. B284002 (Cal. Ct. App. June 3, 2020).
cites § 312.32 1×cited by 0 cases
Where it cites § 312.32
“” ( 21 C.F.R. § 312.32 (a) (2019).) 10 Further, the FDA found no basis for requiring a box warning about the lack of long-term safety data associated with pediatric use of risperidone.”
15
NO FLAGShareholder Rep. Servs. LLC v. Shire US Holdings, Inc., No. 2017-0863-KSJM (Del. Ch. Oct. 12, 2020).
cites § 312.32 1×cited by 0 cases
Where it cites § 312.32
“, JX-308; JX-462; JX-463; JX-767; see 21 C.F.R. § 312.32 (c)(1)(i) (“The sponsor must report any suspected adverse reaction that is both serious and unexpected.”
16
NO FLAGKim v. Allakos Inc., No. 4:20-cv-01720 (N.D. Cal. Mar. 31, 2022).
cites § 312.32 1×cited by 0 casesunknown
Where it cites § 312.32
“” 21 C.F.R. § 312.32 (c)(1)(i). It is 3 the responsibility of each trial investigator, not the company sponsoring the drug trial, to report 4 any serious adverse event and assess whether that event is drug-related.”
17
NEUTRALIgnacuinos v. Boehringer Ingelheim Pharmaceuticas Inc, 490 F. Supp. 3d 533 (D. Conn. 2020).
cites § 312.32 1×cited by 0 casesunknown
Where it cites § 312.32
“” 21 C.F.R. § 312.32 (a). Boehringer also contends that the Plaintiffs’ state law claims asserting a design defect are also preempted by federal law.”
18
NO FLAGMazurek v. Seres Therapeutics, Inc., No. 1:16-cv-11943 (D. Mass. Mar. 30, 2018).
cites § 312.32 1×cited by 0 casesunknown
Where it cites § 312.32
“, CDI recurrence) and there is a “causal relationship between the drug and the event,” 21 C.F.R. § 312.32 (c)(5); see Fed. Drug Admin.”
19
NO FLAGLeclair v. GlaxoSmithKline LLC, No. 1:15-cv-10429 (D. Mass. June 1, 2021).
cites § 312.32 1×cited by 0 casesunknown
Where it cites § 312.32
“” 21 C.F.R. § 312.32 (a). Plaintiffs contend that in a 2005 report summarizing pediatric events involving Zofran, GSK categorized cardiac-related congenital adverse events under six separate SOCs: (1) cardiac disorders; (2) congenital, familial, and genetic disorders; (3)…”
20
NO FLAGSmith v. Antares Pharma, Inc., No. 3:17-cv-08945 (D.N.J. Apr. 28, 2020).
cites § 312.32 1×cited by 0 casesunknown
Where it cites § 312.32
“} Phase 3 studies “are performed after preliminary evidence suggesting effectiveness of the drug has been obtained and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug…”

Show all 21 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199220072022

One bar per year. Tallest: 4 cases in 2018. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D. Mass.4N.D. Cal.2D.N.J.21st Cir.19th Cir.1Cal. Ct. App.1S.D. Cal.1D. Conn.1

The 8 courts with the most citing cases, of 16 courts in all.

By subsection
(a)1 case
Byrd v. Janssen Pharm., Inc., 333 F. Supp. 3d 111 (N.D.N.Y. 2018).“The Court will also set aside the fact that any inpatient hospitalization (at a psychiatric facility) that Plaintiff may still need due to his gynecomastia has (by definition) not been prevented by his 2014 surgery, 8 making it impossible to conclude that gynecomastia has…”

Show all 21 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com